Home › Plasma Cell Cancer › New York
Plasma Cell Cancer clinical trials in New York
6 studies for Plasma Cell Cancer are looking for participants at sites in New York.
Cities in New York
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Mount Sinai, The Tisch Cancer Instutute, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04879043MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06152575A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Memorial Sloan-Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05651932Delayed Toxicities Post-CAR-T
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07665307A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All protocol activities), Commack
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
- and 1 more
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT07052916Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
- University of Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 10, 2025 · NCT05597345From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.